A robust genomic-based prognostic model for the assessment ofcancer stemness and survival for patients with hepatocellularcarcinoma

作     者：Cheng-Li Du Shen-Yu Wei Yun-Hao Chen Kang-Jie Chen Cheng-Li Du;Shen-Yu Wei;Yun-Hao Chen;Kang-Jie Chen

作者机构：Division of Thoracic SurgeryFirst Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Zhejiang University School of MedicineHangzhou 310003China Division of Hepatobiliary Pancreatic SurgeryFirst Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2024年第23卷第1期

页      面：97-102页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This study was supported by a grant from the National Natural Science Foundation of China(82002927) 

主　　题：cancer prognosis Liver 

摘      要：To the Editor:Hepatocellular carcinoma(HCC)is an aggressive malignancy with poor long-term prognosis[1].Liver cancer stem cell(CSC)can drive the metastasis,drug resistance,and recurrence of HCC[2].The regulatory mechanisms about liver cancer stemness have been investigated,which encouraged the identification and characterization of novel prognostic and therapeutic strategies for HCC[3].